# US 2023/0272108 A1 · Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272108 A1
- Document ID: US20230272108A1
- Status: Published application
- Kind: A1
- Application number: 17/956,923
- Filed: 2022-09-30
- Published: 2023-08-31
- Earliest claimed: 2015-03-17
- Assignees: Tilt Biotherapeutics Oy
- Applicants: TILT Biotherapeutics Oy
- Inventors: Akseli Hemminki; Suvi Parviainen; Siri Tähtinen; Ilkka Liikanen; Mikko Siurala
- Web page: https://patentgrep.com/patent/US20230272108A1

## CPC

- C07K 16/30: from tumour cells
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2821: {against ICAM molecules, e.g. CD50, CD54, CD102}
- C07K 16/3092: {against tumour-associated mucins}
- C12N 15/86: Viral vectors
- A61K 2039/585: {wherein the target is cancer}
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2710/00044: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2710/00045: Special targeting system for viral vectors
- C12N 2710/10033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.

## Claims

### Claim 1

A method of treating cancer in a subject, wherein the method comprises administration of an oncolytic adenoviral vector to a subject, wherein the oncolytic adenoviral vector comprises:
i) an adenovirus serotype 5 (Ad5) nucleic acid backbone comprising a 5/3 chimeric fiber knob;
ii) an E2F1 promoter for tumor specific expression of E1A;
iii) a 24 bp deletion (D24) in the Rb binding constant region 2 of adenoviral E1;
iv) a nucleic acid sequence deletion of viral gp19k and 6.7k reading frames; and
v) a nucleic acid sequence encoding a bispecific monoclonal antibody in the place of the deleted gp19k and 6.7k nucleic acid sequence in the E3 region,
wherein the bispecific monoclonal antibody comprises a single chain variable fragment (scFv) specific for a cell surface molecule on immunological effector cells and a scFv specific for a tumor antigen,
wherein the tumor antigen is EpCAM1 or MUC 1 and the cell surface molecule is CD3, and
wherein, in the presence of tumor cells, the bispecific monoclonal antibody is capable of counteracting tumor immunosuppression and promoting the recruitment of T cells to the tumor cells.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method further comprises administration of adoptive cell therapeutic composition to the subject.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the adoptive cell therapeutic composition comprises a cell type selected from a group consisting of a tumor infiltrating lymphocyte (TIL), T-cell receptor modified lymphocytes and chimeric antigen receptor modified lymphocytes.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the adoptive cell therapeutic composition comprises a cell type selected from a group consisting of T-cells, CD8+ cells, CD4+ cells, NK-cells, delta-gamma T-cells, regulatory T-cells, and peripheral blood mononuclear cells.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the adoptive cell therapeutic composition comprises T-cells.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the administration(s) of oncolytic viral vectors and an adoptive cell therapeutic composition to a subject is(are) conducted simultaneously or consecutively, in any order.

### Claim 7 (depends on 2)

The method according to claim 2, further comprising administration of concurrent or sequential radiotherapy, monoclonal antibodies, chemotherapy or other anti-cancer drugs or interventions to a subject.

### Claim 8 (depends on 2)

The method according to claim 2, wherein the method increases the efficacy of adoptive cell therapy in a subject.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the tumor antigen is EpCAM1.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the tumor antigen is MUC 1.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the nucleic acid sequence further encodes for IL-2.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the oncolytic adenoviral vector further comprises an IL-2, TNFalpha, or CD40L transgene.
